Subjects n |
32 |
26 |
39 |
|
Clinical characteristics |
|
|
|
|
Age at follow-up years |
51.7±13.3 |
63.2±11.8+ |
61.9±12.4+ |
0.001 |
Males |
12 (37.5%) |
15 (57.7%) |
28 (71.8%)+ |
0.015 |
BMI kg·m−2 |
25.9 (23.3–28.5) |
28.1 (25.0–30.8) |
28.7 (24.2–33.4) |
0.045 |
Use of medication |
|
|
|
|
ICS in daily use |
20 (62.5%) |
21 (80.8%) |
31 (79.5%) |
0.179 |
ICS dose per day¶ |
800 (400–1000) |
800 (650–1800) |
1000 (775–1500) |
0.282 |
LABA in daily use |
6 (18.8%) |
16 (61.5%)+ |
25 (64.1%)+ |
<0.001 |
LAMA, LTRA or theophylline in daily use |
3 (9.4%) |
7 (26.9%) |
8 (20.5%) |
0.214 |
≥1 antibiotic course during follow-up |
22 (68.8%) |
22 (84.6%) |
30 (76.9%) |
0.366 |
Use of oral steroid courses ever |
9 (28.1%) |
9 (34.6%) |
11 (28.9%) |
0.846 |
Effect of cumulative smoking history |
|
|
|
|
≥1 hospitalisations during follow-up for any respiratory reason |
4 (12.5%) |
6 (23.1%) |
16 (41.0%)+ |
0.023 |
≥1 asthma-related hospitalisations during follow-up |
2 (6.3%) |
5 (19.2%) |
12 (30.8%)+ |
0.035 |
Comorbidities |
0 (0–1) |
2 (1–3)+ |
2 (1–4)+ |
<0.001 |
ACT |
23 (21–25) |
21 (17-24)+ |
21 (17–23)+ |
0.003 |
CAT |
8±5 |
14±7+ |
15±7+ |
<0.001 |